Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020